Multicenter, Double‐Blind, Randomized Trial of Emricasan in Hepatitis C–Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis-Reference-Cited by-同舟云学术

Multicenter, Double‐Blind, Randomized Trial of Emricasan in Hepatitis C–Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis

Published:2020-12-29 Issue:4 Volume:27 Page:568-579
ISSN:1527-6465
Container-title:Liver Transplantation
language:en
Short-container-title:Liver Transpl.

Author:

Weinberg Ethan M.¹,Curry Michael P.²,Frenette Catherine T.³^ORCID,Regenstein Fredric G.⁴,Schiff Eugene R.⁵,Goodman Zachary D.⁶,Robinson James M.⁷,Chan Jean L.⁷,Imperial Joanne C.⁷,Reddy K. Rajender¹^ORCID

Affiliation:

1. Department of Medicine University of Pennsylvania Philadelphia PA

2. Department of Medicine Beth Israel Deaconess Medical Center Boston MA

3. Center for Organ and Cell Transplantation Scripps Clinic La Jolla CA

4. Department of Medicine Tulane Medical Center New Orleans LA

5. Center for Liver Diseases University of Miami Miami FL

6. Hepatic Pathology Consultation and Research Inova Fairfax Hospital Falls Church VA

7. Conatus Pharmaceuticals San Diego CA

Funder

Novartis

Publisher

Wiley

Subject

Transplantation,Hepatology,Surgery

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/lt.25934

Reference34 articles.

1. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation

2. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study

3. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection

4. Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the potential of drug repurposing for liver diseases: A comprehensive study;Life Sciences;2024-06

2. Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective;Clinical Pharmacology & Therapeutics;2023-07-29

3. Emricasan for the treatment of liver cirrhosis: a meta-analysis of randomized controlled trials;African Health Sciences;2023-07-13

4. Preclinical Models and Promising Pharmacotherapeutic Strategies in Liver Fibrosis: An Update;Current Issues in Molecular Biology;2023-05-11

5. Natural killer cells induce HIV-1 latency reversal after treatment with pan-caspase inhibitors;Frontiers in Immunology;2022-12-06